Table 7. Other Outcomes.
| Author | Surgery | Significant AEa | QOL | Infections | LOS, median (IQR) | Mortality |
|---|---|---|---|---|---|---|
| Cladellas et al, 2012 [32] | VR | None | NR | Decreased: 8% vs. 24%, P = 0.01 | Shorter: 10 days (8 - 14) vs. 15 days (10 - 27), P < 0.01 | Decrease: 9% vs. 23%, P = 0.04 |
| Urena et al, 2017 [34] | VR (TAVI) | No diff | NR | No diff | No diff | No diff |
| Johansson et al, 2015 [36] | CABG, VR | No diff | NR | No diff | NR | No diff |
| Padmanabhan et al, 2018 [35] | CABG, VR | None | No diff | No diff | No diff | No diff |
| Garrido-Martin et al, 2012 [33] | CABG, VR | None | NR | Not increased | NR | NR |
| Spahn et al, 2019 [37] | CABG, VR | No diff | NR | No diff | No diff | No diff |
aAs defined by study. AE: adverse event; CABG: coronary artery bypass grafting; diff: difference; IQR: interquartile range; LOS: length of stay; NR: not reported; QOL: quality of life; TAVI: trans-aortic valve implantation; VR: valve replacement.